GLP-1 Consumer Protection · Telehealth Platforms
Hims, Ro, and LifeMD GLP-1 Programs: What's Changing and What Customers Should Do
Published June 2026 — Current as of FDA shortage resolution
Hims & Hers Health, Ro (Roman Health), and LifeMD are the three most prominent direct-to-consumer telehealth companies that built large-scale GLP-1 weight management programs on the availability of compounded semaglutide and tirzepatide. Together they served hundreds of thousands of patients who found brand-name GLP-1 pricing out of reach.
Those programs are ending — not because the companies decided to exit, but because the FDA's resolution of the national drug shortages eliminated the legal basis that made the programs possible. This guide is for customers of these platforms: what each company offered, what is happening now, how to cancel and get a refund, and what to watch out for as these companies pivot.
Why These Programs Are Ending
All three companies built their GLP-1 programs on the same legal foundation: the FDA drug shortage exception. Under federal law, compounding pharmacies cannot mass-produce drugs that are "essentially a copy" of commercially available FDA-approved medications — with one exception: when the FDA officially places a drug on its drug shortage list.
In 2022–2023, the FDA added semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) to the shortage list due to manufacturing capacity failing to keep up with surging demand. That shortage designation opened a legal window. Hims, Ro, LifeMD, and dozens of other telehealth platforms moved quickly into that window, partnering with compounding pharmacies — mostly large-scale 503B outsourcing facilities — to offer compounded GLP-1 at $99–$299/month.
The FDA has now declared both shortages resolved. The window has closed. Without an active shortage designation, the legal basis for mass-market compounded GLP-1 programs no longer exists. Compounding pharmacies that continue mass-producing semaglutide or tirzepatide for general sale face FDA enforcement action and DOJ referrals. The telehealth companies that depended on those pharmacies for supply must now find a different path. Full regulatory background →
The Three Programs at a Glance
| Feature | Hims & Hers | Ro (Ro Body) | LifeMD |
|---|---|---|---|
| Company type | Publicly traded (NYSE: HIMS) | Private | Publicly traded (NASDAQ: LMD) |
| GLP-1 program name | Hims / Hers Weight | Ro Body | Operates through multiple brands |
| Medications offered | Compounded semaglutide, tirzepatide | Compounded semaglutide, tirzepatide | Compounded semaglutide, tirzepatide |
| Approx. program cost | ~$149–$299/month | ~$99–$299/month | ~$149–$289/month |
| Regulatory impact | Identical — FDA shortage resolution applies equally | Identical — FDA shortage resolution applies equally | Identical — FDA shortage resolution applies equally |
| Pivot strategy | Brand-name prescribing + savings program facilitation | Brand-name prescribing + program restructuring | Brand-name prescribing + program restructuring |
| Cancellation | Account portal or support contact | Account portal or support contact | Account portal or support contact |
The key takeaway from the table: the regulatory situation is identical for all three companies. The differences that matter for you as a customer are the specific steps to cancel, the refund policies, and what transitional programs they're offering as alternatives.
Hims & Hers Health
Hims & Hers was one of the most aggressive marketers of compounded GLP-1 medications, scaling a weight management program that became a significant portion of the company's revenue and subscriber growth. The company promoted compounded semaglutide and tirzepatide directly to consumers at prices well below brand-name retail — a strategy that attracted significant attention from pharmaceutical manufacturers, regulators, and investors.
As a publicly traded company, Hims & Hers has had to make public statements about the impact of FDA shortage resolutions on its GLP-1 business. The company has disclosed pivoting its weight management offering toward facilitating access to FDA-approved brand-name medications, weight management programs, and other services — a model that is legally sustainable but fundamentally different from what most customers were paying for.
The price reality of Hims & Hers' brand-name pivot: FDA-approved Wegovy retails for over $1,000/month. Hims may facilitate savings card access for commercially insured patients, which can reduce cost substantially — but patients without qualifying insurance do not benefit from savings cards, and the path to near-zero cost requires insurance prior authorization that many patients don't have and may not qualify for. Patients should ask Hims directly: what is my specific monthly cost under the transition program, and what happens if my insurance coverage changes?
- Log into your account and navigate to subscription or plan settings to find cancellation options.
- Send a written cancellation notice through the in-app messaging system or support email — create a paper trail with a date stamp.
- Explicitly request a refund of any prepaid balance for services not yet delivered. State this clearly in writing.
- If Hims offers to transition you to a brand-name program, ask for the exact monthly cost, in writing, before agreeing to anything.
- If you do not receive a timely response or a satisfactory refund, contact your credit card issuer to dispute charges for undelivered services.
Ro (Roman Health / Ro Body)
Ro built its GLP-1 weight management business under the "Ro Body" brand, expanding from its original men's health (Roman) and women's health (Rory) foundations into metabolic health and weight management. Like its competitors, Ro Body offered compounded semaglutide and tirzepatide through prescribers and 503B compounding pharmacy partnerships.
As a private company, Ro has fewer mandatory public disclosure obligations than Hims or LifeMD, which means customers may have received less proactive communication about program changes. Ro has been restructuring its weight management offering in response to the regulatory changes — the specific form of its transition program should be confirmed directly with the company, as the specifics may continue to evolve.
One important note for Ro Body customers: Ro originally promoted the program with pricing and commitments that may differ from what they are now able to deliver. If you signed up for a specific program at a specific price, the company's inability to deliver the program as originally described gives you a contractual basis to cancel and request a refund. The pivot to brand-name prescribing at fundamentally different price points is a material change to what you purchased.
- Log into your Ro account and check for any program change notices or updated terms.
- Send a written cancellation request through the platform's support messaging or email — clearly state you are canceling and requesting a refund of prepaid amounts.
- If Ro has already transitioned you to a different program or medication without your affirmative consent, request that the transition be reversed and that you receive a refund for any charges under the new terms you did not agree to.
- Document all communications with dates. If you do not receive a response within 7 business days, escalate to a credit card chargeback.
LifeMD
LifeMD operates a portfolio of telehealth brands, including RexMD (originally men's health) and weight management programs that incorporated compounded GLP-1 offerings. As a publicly traded company, LifeMD has disclosed the regulatory and business risks from compounding crackdowns in its SEC filings — its GLP-1 program represented a meaningful part of its growth strategy, and the transition away from compounded medication is a material business change.
LifeMD's transition strategy has focused on maintaining its patient relationships through brand-name prescribing and comprehensive weight management services beyond medication alone. The company has emphasized the clinical supervision component of its programs as a value driver independent of the medication source. For existing customers, however, the practical question remains: what does the medication cost under the new model, and what are your options if that cost is out of reach?
LifeMD customers should be particularly alert to automatic subscription continuation and the possibility of being billed for services under changed terms. If your program has changed materially — different medication, different price, different delivery model — and you did not affirmatively agree to those changes, you have the right to cancel and to receive a refund for the changed period.
- Check your LifeMD account for any program update notices, especially changes to medication type or pricing.
- Send a written cancellation request through the platform — note the date clearly.
- If your program changed to brand-name medication at a higher price without clear advance notice, request a refund of any charges above your original subscription cost.
- Review your credit card statements for LifeMD charges after any program change notices — compare to what you agreed to when you enrolled.
- File a complaint with the FTC (ftc.gov/complaint) or your state attorney general if you believe your subscription was changed without clear notice and your consent.
Other Telehealth Platforms Affected by the Same Changes
Hims, Ro, and LifeMD are the three largest players, but the same regulatory changes affect every telehealth platform that offered compounded GLP-1 programs. This includes Eden (Eden.health), Henry Meds, Noom Weight, Structure Health, Mochi Health, and numerous smaller regional telehealth platforms. The legal analysis is identical for all of them: the FDA shortage exception they were relying on no longer applies.
If you are a customer of any telehealth GLP-1 program — not just the three named in this guide — the same principles apply to your cancellation and refund rights.
The Hidden Risk: Automatic Transitions to Higher-Cost Programs
The most significant consumer protection risk in the current transition period is the "automatic upgrade" — a platform that quietly pivots your subscription from a $199/month compounded program to a $999+/month brand-name facilitation service, often framed as a seamless "upgrade" to a better program.
Federal Trade Commission regulations on negative option and subscription programs require that companies:
- Clearly disclose any material changes to subscription terms before they take effect
- Obtain your affirmative consent before making changes that increase your cost
- Make cancellation easy — not buried in a multi-step process or conditioned on speaking to a retention agent
- Provide a straightforward way to obtain a refund for prepaid services that are not delivered
A telehealth company that transitions you from compounded to brand-name medication without a clear, advance, conspicuous notice — and without giving you a genuine opportunity to cancel — may be violating FTC rules. This is particularly true if the new program involves a significantly higher cost per month.
What These Companies Are Offering Instead — And the Price Reality
All three companies have announced or implemented some form of pivot to brand-name GLP-1 prescribing. The pitch is essentially: "We can't provide compounded GLP-1 anymore, but we can help you access Wegovy or Zepbound, potentially with savings programs or insurance coverage facilitation."
This is a legitimate service. Getting help navigating prior authorization, finding the right savings card program, and having prescribers who understand GLP-1 management has real value. But you need to understand the economics before accepting any transition offer:
When the brand-name pivot works for you
- You have commercial insurance that covers GLP-1s for weight management, or can be persuaded to with prior authorization — and a savings card brings your cost to $0–$25/month
- You qualify for patient assistance — if your income falls within Novo Nordisk's or Eli Lilly's PAP thresholds, brand-name medication may be available free
- The telehealth company is handling the PAP application as part of their transition service, at no additional cost to you
When the brand-name pivot does not work for you
- You are on Medicare or Medicaid — savings cards are not available, and the economics do not work for most of these patients
- Your commercial insurance does not cover GLP-1s for weight management — you face retail pricing with no savings card benefit
- You don't qualify for PAP — and the telehealth company is charging you a premium for services that don't meaningfully reduce your medication cost
- The company charges a "management fee" on top of the medication cost, making the total cost significantly higher than the alternative of working directly with a prescriber and manufacturer programs
The honest version of the transition conversation that you deserve to have: "What specifically will you do for me that I cannot do myself, and what will my total monthly cost be?" If a telehealth company cannot answer that question clearly, that is your answer.
Your Cancellation and Refund Rights
Regardless of which platform you're on, your rights are grounded in the same legal framework. Here's the short version:
For a more detailed treatment of your rights, including how to draft an effective written cancellation request, see our companion guide: Your Compounded GLP-1 Program Is Ending: What to Do Now.
Frequently Asked Questions
These companies' compounded GLP-1 programs lost their primary legal basis when the FDA declared semaglutide and tirzepatide shortages resolved. Mass-market compounded GLP-1 programs no longer have a legal basis under federal law. The companies themselves are not illegal — they can still prescribe and facilitate access to FDA-approved brand-name GLP-1 medications. But their model of providing lower-cost compounded GLP-1 at scale has ended.
If you have prepaid for services or medication that can no longer be delivered as promised, you have a strong legal basis for a refund of the undelivered portion under basic contract law. Contact the company in writing requesting cancellation and a refund. If they refuse or delay, initiate a credit card chargeback. Document all communications. The FTC's subscription regulations support your right to cancel and to receive refunds for prepaid undelivered services.
That depends on your cost situation. Before agreeing to any transition, ask for your specific monthly cost in writing, how long that price is guaranteed, and whether it depends on insurance coverage that might change. If Hims is facilitating savings card access for commercially insured patients, the net cost could be manageable. If they are simply prescribing brand-name medication at retail with no meaningful savings facilitation, the economics are radically different from what you were paying for compounded GLP-1.
Federal Trade Commission regulations require clear disclosure of material subscription changes and affirmative consent before implementing them. If you were moved to a significantly more expensive program without advance notice and your consent, you may have a claim under FTC rules. Contact the company in writing to dispute the change and request a refund of overcharges. If they do not respond, initiate a credit card chargeback and file complaints with the FTC and your state attorney general.
Mass-market compounded GLP-1 programs no longer have a legal basis. Patient-specific compounding by 503A pharmacies may remain available in narrow cases where a prescriber documents a specific, individualized medical need that commercial products cannot address — such as a documented allergy to an inactive ingredient. General desire for a lower-cost alternative is not sufficient. Most legitimate compounders are being very cautious about this.
The programs had a real legal basis when they were built — the FDA drug shortage exception is a recognized provision of federal law. The companies were not clearly acting illegally at the time. They were operating in a regulatory window created by the FDA's shortage designation, and that window always carried the risk of closing when the FDA determined the shortage was resolved. Some companies marketed more aggressively than the underlying regulatory stability warranted. The window is now closed.
The options in order of accessibility: (1) manufacturer patient assistance programs, which provide brand-name GLP-1 free to qualifying patients — check Novo Nordisk's Wegovy Assist and Eli Lilly's Lilly Cares Foundation; (2) manufacturer savings cards, which bring cost to near zero for commercially insured patients with insurance coverage for GLP-1s; (3) generic liraglutide, which is FDA-approved, available, and less expensive than semaglutide or tirzepatide, with a lower average weight loss ceiling. For a full ranked breakdown, see our transition options guide.